Brain cancer patients may face a more complex therapeutic challenge than previously understood, as glioblastoma cells appear to hijack a critical immune protein for their own survival advantage. This discovery could explain why promising immunotherapies targeting this pathway have failed in clinical trials.
Researchers identified that CD47, traditionally known as an immune checkpoint that helps cancer cells evade destruction by immune cells, actually serves a dual role in glioblastoma multiforme (GBM). The protein directly stabilizes ROBO2, a guidance receptor crucial for tumor cell migration and invasion, by preventing its degradation through the ITCH ubiquitin ligase system. This cell-intrinsic mechanism operates independently of CD47's well-established immune evasion functions, creating a previously unknown pathway that promotes tumor progression from within cancer cells themselves.
This finding represents a significant shift in understanding glioblastoma biology and may explain the disappointing clinical results of anti-CD47 immunotherapies in brain cancer patients. Unlike other cancer types where blocking CD47 shows promise by unleashing immune responses, glioblastoma appears to use CD47 as an internal survival mechanism that operates regardless of immune system activity. The research suggests that effective GBM treatment may require targeting both CD47's immune evasion role and its newly discovered cell-intrinsic functions. However, this dual mechanism also presents therapeutic challenges, as completely blocking CD47 could have broader physiological consequences. The study's focus on protein-protein interactions and ubiquitination pathways opens new avenues for drug development, though translating these molecular insights into effective treatments will require extensive further research and careful consideration of potential side effects in healthy brain tissue.